TORONTO, ONTARIO -- (Marketwired) -- 01/31/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its second Phase 1 clinical trial with TTI-621 ( ...
↧